GILD
reuters.dev
http://www.google.com/url?source=finance&q=http%3A%2F%2Fwww.reuters.com%2Ffinance%2Fstocks%2FGILD.O%2Fkey-developments%2Farticle%2F2523374&ei=n4aaUtjHJIj_sgfnKQ&usg=AFQjCNFK2KtF02FA1w_3mgTbvzqOtiJJgw
Gilead Sciences, Inc. Announces Sustained Virologic Response Data For 12-Week Regimen Of GS-7977 Plus Pegylated Interferon And Ribavirin In Genotype One Hepatitis C Patients
Thursday, 19 Apr 2012 05:00am EDT
Gilead Sciences, Inc. announced interim data from a Phase II trial (ATOMIC) examining a 12-week course of treatment with the once-daily nucleotide GS-7977 plus pegylated interferon (Peg-IFN) and ribavirin (RBV) in treatment-na√Øve patients with genotype one chronic hepatitis C virus (HCV) infection. The study found that 90%of patients (n=47/52, missing data equals failure analysis) achieved a 12-week sustained virologic response (SVR12), defined as maintaining undetectable viral load (HCV RNA
